Next Article in Journal
Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?
Next Article in Special Issue
A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
Previous Article in Journal
Epsilon-Globin HBE1 Enhances Radiotherapy Resistance by Down-Regulating BCL11A in Colorectal Cancer Cells
Previous Article in Special Issue
Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle

SERPINB2 Is a Novel Indicator of Cancer Stem Cell Tumorigenicity in Multiple Cancer Types

Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Korea
Department of Molecular Medicine, School of Medicine, Gachon University, Incheon 406-840, Korea
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea
Department of Obstetrics and Gynecology, Gachon University Gil Medical Center, Incheon 21565, Korea
Department of Genome Medicine and Science, College of Medicine, Gachon University, Incheon 21565, Korea
Department of Life Sciences, Gachon University, Seongnam 21936, Korea
Department of Otolaryngology-Head and Neck Surgery, Gil Medical Center, Gachon University School of Medicine, Incheon 21565, Korea
Department of Pathology, Gachon University Gil Medical Center, Incheon 21565, Korea
Department of Biomedical Science, Jungwon University, 85 Goesan-eup, Munmu-ro, Goesan-gun, Chungcheongbuk-do 367-700, Korea
Authors to whom correspondence should be addressed.
These authors contribute equally to this work.
Cancers 2019, 11(4), 499;
Received: 19 February 2019 / Revised: 2 April 2019 / Accepted: 3 April 2019 / Published: 8 April 2019
(This article belongs to the Special Issue Advances in Cancer Stem Cell Research)
PDF [35568 KB, uploaded 24 April 2019]


Drug resistance is one of the major characteristics of cancer stem cells (CSCs) and a mechanism of tumor recurrence. Therefore, selectively targeting CSCs may be an effective therapeutic strategy to overcome cancer recurrence. In the present study, we found that exposure to tumorigenic compounds significantly increased the growth potential and stem-cell-like properties of various CSCs. Early-response genes involved in tumorigenesis can be used as specific markers to predict potential tumorigenicity. Importantly, for the first time we identified, a labile tumorigenic response gene—SERPINB2—and showed that tumorigenic compound exposure more profoundly affected its expression in CSCs than in non-stem cancer cells, although both cells exhibit basal expression of SERPINB2 in multiple cancer types. Our data also revealed a strong relationship between the significantly enhanced expression of SERPINB2 and metastatic progression in multiple cancer types. To the best of our knowledge, this is the first study to focus on the functions of SERPINB2 in the tumorigenicity of various CSCs and these findings will facilitate the development of promising tumorigenicity test platforms. View Full-Text
Keywords: cancer stem cells; SERPINB2; tumorigenicity; stem cell-like properties cancer stem cells; SERPINB2; tumorigenicity; stem cell-like properties

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Lee, N.-H.; Park, S.-R.; Lee, J.W.; Lim, S.; Lee, S.-H.; Nam, S.; Kim, D.Y.; Hah, S.Y.; Hong, I.-S.; Lee, H.-Y. SERPINB2 Is a Novel Indicator of Cancer Stem Cell Tumorigenicity in Multiple Cancer Types. Cancers 2019, 11, 499.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top